Licensing status

Publication and contact information


Breast cancer

Chemokine CXC motif ligand 10 (CXCL10; IP-10)

In vitro and mouse studies suggest antibodies targeting CXCL10 could help treat breast cancer. In human breast cancer tissue samples, gd Treg cells, which suppress antitumor immunity, accumulated in tumors but not in healthy tissue. In mice bearing subcutaneous human breast tumors and adoptively transferred human gd Treg cells, a CXCL10-neutralizing antibody prevented tumor gd Treg cell accumulation and decreased tumor growth compared with an isotype control antibody. Next steps could include testing antibodies against CXCL10 in additional breast cancer models.
Bristol-Myers Squibb Co.'s MDX-1100, a mAb targeting CXCL10, is in Phase II testing to treat inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). NovImmune S.A.'s CXCL10 mAb, NI-0801, is in Phase II testing for liver disease and cirrhosis.

SciBX 6(38); doi:10.1038/scibx.2013.1055
Published online Oct. 3, 2013

Patent and licensing status unavailable

Ye, J. et al. Cancer Res.; published online Aug. 19, 2013;
Contact: Guangyong Peng, Saint Louis University, St. Louis, Mo.